Equity raise and third-party capital update – Biotech Investments

Hardman & Co Research

Hardman & Co Q&A on Duke Capital (DUKE): Equity raise and third-party capital update

20-Nov-2024 / 10:30 GMT/BST

The issuer is solely responsible for the content of this announcement.

Analyst interview | Financials

Q&A on Duke Capital (DUKE) | Equity raise and third-party capital update
 

Duke Capital (DUKE) is the topic of conversation when Hardman & Co Analyst Mark Thomas joins DirectorsTalk.

In this interview, Mark discusses recent developments at Duke Capital, touching on key topics such as their equity raise and progress towards incorporating third-party capital. Mark explains how these moves could shape Duke’s growth trajectory and mitigate risks, as well as the significance of their evolving capital model. He also addresses potential risks facing the company, providing a well-rounded perspective on their financial strategy.

Listen to the interview here.

 

If you are interested in meeting the company, you can register your interest here.
 

 

Hardman & Co Research can be accessed for free under MiFID. Please click here to read the statement.

About Hardman & Co: Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259. Attention is drawn to the important disclaimers at the end of the report.


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


End of Announcement – EQS News Service

show this